Skip to main content
Monday, November 16, 2026Nov 16

2 US scientists awarded Balzan Prize for cancer research

Salvatore Veca attends a press conference to present a 2017 Balzan's prize edition, in Milan, Italy, Monday, Sept. 11, 2017. James Allison of the University of Texas MD Anderson Cancer Center and Robert Schreiber of the Washington School of Medicine were announced Monday as winners of the 750,000 Swiss franc (660,000 euro, $790,000) prize. They were cited for work that has helped use antibody treatments that has increased the survival of patients with metastic melanoma. (AP Photo/Antonio Calanni)
Salvatore Veca attends a press conference to present a 2017 Balzan's prize edition, in Milan, Italy, Monday, Sept. 11, 2017. James Allison of the University of Texas MD Anderson Cancer Center and Robert Schreiber of the Washington School of Medicine were announced Monday as winners of the 750,000 Swiss franc (660,000 euro, $790,000) prize. They were cited for work that has helped use antibody treatments that has increased the survival of patients with metastic melanoma. (AP Photo/Antonio Calanni)

MILAN (AP) – Two U.S. scientists whose work has contributed to creating immunological treatments for cancer are among the winners of this year’s Balzan Prizes, announced Monday, recognizing scholarly and scientific achievements.

James Allison of the University of Texas MD Anderson Cancer Center and Robert Schreiber of the Washington University School of Medicine were cited for their work on antibody treatments that has increased the survival of patients with metastatic melanoma.

The Balzan Foundation awards two prizes in the sciences and two in the humanities each year, rotating specialties to highlight new or emerging areas of research and sustain fields that might be overlooked elsewhere. Recipients receive 750,000 Swiss francs ($790,000), half of which must be used for research, preferably by young scholars or scientists.

Nobel Prize-winner Jules Hoffman, a presenter of the awards, said the work focusing on using the immune system to fight cancer, expanding from the traditional treatments of removal, radiation and chemotherapy, has already had success in 25 to 30 percent of melanoma patients in a study who had previously gone through the traditional battery of treatments. It is now being developed for small cell lung cancer and rectal cancer.

Other winners are: